We would like to bring a paper that was recently published in JAHA (full text) to your attention. This meta-analysis of all RCTs comparing drug eluting technology (DET eluting stents or balloons) to standard endovascular therapy (bare stents or standard balloons) in the SFA demonstrated an increase in mortality in patients receiving DET devices at 2 and 5 years. However, this was an increase in all-cause mortality and the contribution of paclitaxel to this increased mortality is unknown at this time.
CIRSE is working with other interested parties to clarify the situation and we hope that the situation will become clearer in the first quarter of 2019.
Please note that this meta-analysis only relates to RCTs of paclitaxel coated balloons or stents in the SFA and not to other vascular territories.